Mother-to-child transmission of HIV in the United States: Many HIV-infected women are now planning to have children. What are the risks to mother and infant?

American Journal of Nursing

Volumn 106, Issue 7, 2006, Pages 56-64

  Cibulka, Nancy J ^a,b  

^a BARNES JEWISH HOSPITAL   (United States)

^b MARYVILLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746645966     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000446-200607000-00029     Document Type: Review

References (47)

1. Centers for Disease Control and Prevention. HIV/AIDS surveillance report: cases of HIV infection and AIDS in the United States, 2004. Atlanta: The Centers; 2005. Vol. 16. http://www.cdc.gov/hiv/topics/surveillance/resources/ reports/2004report/default.htm.
2. National Institute of Allergy and Infectious Diseases. HIV infection in minority populations. 2005 Apr. Accessed on 2006 Mar 20. http://www.niaid.nih. gov/factsheets/Minor.htm.
3. Cooper ER, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29(5):484-94.
4. Perinatal HIV Guidelines Working Group, Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States; 2005 Nov 17. http://www.aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf.
5. Mofenson LM, McIntyre JA. Advances and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000;355(9222):2237-44.
6. Chen JL, et al. Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect 2001;33(4):144-52, 165.
7. Shannon M. Antiretroviral therapy in HIV-infected pregnant women and their infants: current interventions and challenges. J Perinat Neonatal Nurs 2002;16(2):1-25.
8. Mofenson LM. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 1997;421:1-9.
9. Kreiss J. Breastfeeding and vertical transmission of HIV-1. Acta Paediatr Suppl 1997;421:113-7.
10. Revised recommendations for HIV screening of pregnant women. MMWR Recomm Rep 2001;50(RR-19):63-85.
11. Garcia PM, et al., for the Women and Infants Transmission Study Group. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341(6):394-402.
12. Mofenson LM, et al., for the Pediatric AIDS Clinical Trials Group Study 185 Team. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341(6):385-93.
13. Dickover RE, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996;275(8):599-605.
14. Thea DM, et al., for the New York City Perinatal HIV Transmission Collaborative Study Group. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. AIDS 1997;11(4):437-44.
15. Fiore JR, et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003;17(15):2169-76.
16. Ioannidis JP, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001;183(4):539-45.
17. Landesman SH, et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. N Engl J Med 1996;334(25):1617-23.
18. Simonds RJ, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS 1998;12(3):301-8.
19. Lambert JS, et al. Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection. Clin Diagn Lab Immunol 2005;12(5):622-31.
20. Lee MJ, et al. Maternal syphilis and vertical perinatal transmission of human immunodeficiency virus type-1 infection. Int J Gynaecol Obstet 1998;63(3):247-52.
21. Nair P, et al. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr 1993;6(3):298-302.
22. Burns DN, et al. Cigarette smoking, premature rupture of membranes, and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Defic Syndr 1994;7(7):718-26.
23. Minkoff H, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995;173(2):585-9.
24. International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 - a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340(13):977-87.
25. Maiques V, et al. Intrapartum fetal invasive procedures and perinatal transmission of HIV. Eur J Obstet Gynecol Reprod Biol 1999;87(1):63-7.
26. Shapiro DE, et al., for the Pediatric AIDS Clinical Trials Group protocol 076 Study Group. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Obstet Gynecol 1999;94(6):897-908.
27. Turner BJ, et al. Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14(4):327-37.
28. Peterson PK, et al. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures. Involvement of transforming growth factor-beta. J Immunol 1991;146(1):81-4.
29. Peterson PK, et al. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990;4(9):869-73.
30. Rodriguez EM, et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 1996;10(3):273-82.
31. European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353(9158):1035-9.
32. Mandelbrot L, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280(1):55-60.
33. Semprini AE, et al. The incidence of complications after caesarean section in 156 HIV-positive women. AIDS 1995;9(8):913-7.
34. American College of Obstetricians and Gynecologists. Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection. Washington, DC: The College; 2000 May. ACOG Committee Opinion No. 234.
35. Connor EM, et al., for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331(18):1173-80.
36. Hessol NA, et al. Epidemiology and natural history of HIV infection in women. In: Anderson JR, editor. A guide to the clinical care of women with HIV. Rockville, MD: U.S. Department of Health and Human Services; 2005. p. 1-34. ftp://ftp.hrsa.gov/hab/WG05chap1.pdf.
37. Institute of Medicine. Natural history, detection, and treatment of HIV infection in pregnant women and newborns. In: Reducing the odds: preventing perinatal transmission of HIV in the United States. Washington, DC: National Academies Press; 1999. p. 45-53.
38. Sperling RS, et al., for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335(22):1621-9.
39. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 2006 May 4. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
40. Guay LA, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354(9181):795-802.
41. Perinatal HIV Guidelines Working Group, Public Health Service Task Force. Safety and toxicity of individual antiretroviral agents in pregnancy; 2005 Nov 17. http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGLSafetyTox_Sup.pdf.
42. Culnane M, et al., for the Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999;281(2):151-7.
43. Sperling RS, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998;12(14):1805-13.
44. Advancing HIV prevention: new strategies for a changing epidemic - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52(15):329-32.
45. Sansom SL, et al. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission. Obstet Gynecol 2003;102(4):782-90.
46. Wade NA, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339(20):1409-14.
47. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002;51(RR-6):1-78.